Icatibant for patients with type III hereditary angioedema an updated review of clinical effectiveness and harms
The purpose of this report is to review the clinical effectiveness and safety of icatibant when it is used in patients with Type III HAE. This report is an update of a previous CADTH Rapid Response report (2014),15 which found inconclusive evidence from two observational studies to support the use o...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
March 09, 2017, 2017
|
| Edition: | Version 1.0 |
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this report is to review the clinical effectiveness and safety of icatibant when it is used in patients with Type III HAE. This report is an update of a previous CADTH Rapid Response report (2014),15 which found inconclusive evidence from two observational studies to support the use of icatibant in Type III HAE patients |
|---|---|
| Item Description: | Supplement to: Icatibant for patients with type III hereditary angioedema. February 6, 2014 |
| Physical Description: | 1 PDF file (20 pages) illustrations |